Immuneering Corporation, a clinical oncology company focused on developing cancer treatments, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026. The company is advancing its lead drug candidate, atebimetinib, an oral MEK inhibitor aimed at improving survival in cancers driven by RAS, RAF, and MAPK pathways, including pancreatic cancer. This presentation offers investors insight into Immuneering's innovative approach and ongoing pivotal trials, including the global MAPKeeper 301 study. The event will be webcast live and archived for later viewing.
Immuneering's upcoming presentation at the Guggenheim Healthcare Innovation Conference coincides with a strong day for health-sector stocks on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 04:11 WIB: out of 150 priced US health-sector stocks, 108 rose and 42 fell. Notable movers include LQDA at USD 47.20 with an 11.85% increase but 96% sell order activity, RVMD at USD 217.00 up 11.72%, and HCA at USD 510.87 rising 10.37% with 65% buy order activity and a typical hold time of 77 days.
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
